Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 4/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.48 |
| ▸ | VCP | P55072 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640626 | 1.00 | PDCD1 (0.48) | PDCD1CD274VCPKDM4EUSP30 | |
| SCHEMBL30477888 | 0.90 | PDCD1 (0.55) | PDCD1CD274VCPKDM4EMAPT | |
| SCHEMBL19640613 | 0.90 | PDCD1 (0.55) | PDCD1CD274VCPKDM4EMAPT | |
| SCHEMBL19640633 | 0.85 | PDCD1 (0.48) | PDCD1CD274VCPUSP30MAPT | |
| SCHEMBL24041222 | 0.85 | CD274 (0.53) | PDCD1CD274VCPKDM4EMAPT | |
| SCHEMBL19640659 | 0.85 | CD274 (0.53) | PDCD1CD274VCPKDM4EMAPT | |
| SCHEMBL19640609 | 0.84 | CD274 (0.53) | PDCD1CD274VCPMAPTHTR7 | |
| SCHEMBL19640563 | 0.84 | CD274 (0.53) | PDCD1CD274VCPMAPTHTR7 | |
| SCHEMBL19640562 | 0.84 | CD274 (0.53) | PDCD1CD274VCPMAPTHTR7 | |
| SCHEMBL19640695 | 0.84 | PDCD1 (0.53) | PDCD1CD274VCPKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673883-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | PDCD1 157/4885CD274 88/4885VCP 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.